Human Enhancement Drugs by van de Ven, Katinka; Mulrooney, Kyle J. D.; McVeigh, Jim;

Short description:

This volume provides fresh insights into sports doping as well as under-researched areas, offering practical and theoretical knowledge for academics, practitioners and policymakers. Key features include a global perspective, contributions from leading experts, and coverage of novel topics.

Long description:

Offering an in-depth, multidisciplinary exploration of drugs used to enhance the structure and function of muscle, weight loss, the appearance of the skin and hair, sexual function and behaviour, cognitive function, and mood and social behaviour, this book builds on the first volume by investigating the categorising of these drugs, new populations, emerging issues and harm reduction strategies, advancing the global understanding of human enhancement.

This volume provides fresh insights into sports doping as well as under-researched areas, offering practical and theoretical knowledge for academics, practitioners and policymakers. Key features include a global perspective, contributions from leading experts, and coverage of novel topics such as microdosing, rural drug use and sexualised drug use. By bridging theory and practice, the book equips readers with the knowledge and tools to address the complexities of HED use, including harm reduction and policy challenges.

Human Enhancement Drugs: Volume Two is designed for academics, students (undergraduate and postgraduate), health professionals and anti-doping officials. This book is ideal for public health, sports science, criminology, sociology and law modules, among others. Its interdisciplinary and practice-based approach ensures relevance across diverse educational and professional settings.

Table of Contents:

1 Reflecting on the current human enhancement drugs categorisation and new directions to consider  PART I: Anabolic androgenic steroids and other drugs associated with the development of lean muscle  2 Anabolic androgenic steroid use: epidemiology, risk factors and adverse effects  3 On the female image and performance enhancing drugs experience  4 Thinking in systems to understand and respond to harmful AAS use  5 The Haarlem experience: an outpatient clinic for users of anabolic steroids  6 Becoming allies: combining professional and community-based image and performance enhancing drug harm reduction efforts  7 “Dropping off the edge of a cliff”: a qualitative exploration of the cessation of anabolic androgenic steroid use in the United Kingdom  PART II: Lifestyle drugs  8 Human enhancement drugs in rural settings: exploring the role of place and space in anabolic-a ndrogenic steroid use  9 Contextualising substance use among professionals in Canada  10 Human enhancement modalities: microdosing psychedelics  11 Enhancing sexual and psychosocial experiences: sexualised drug use among men who have sex with men  12 “Filling the gaps”: understanding oil injection for cosmetic enhancement  13 Cognitive enhancing drug use in an age of neoliberalism: issues and implications for future potential legislation and policy  PART III: Sports doping  14 Why anti- doping?  15 Involving stakeholders to develop anti- doping education: bridging the gap between research and practice  16 Seven failed arguments for the inclusion of trans women in elite sport  17 Image and performance enhancing drugs and intersecting populations: recreational Welsh rugby union players and gym users  18 “Doping cases in football are always involuntary”: a critical review